AUS
NZ
UK
CA
USA
IND
Highlights
- CSL has the largest market capitalisation (AU$131.32 billion) in the ASX health care space as of 31 May 2022
- In 2020/21, CSL invested US$1,001 million in R&D activities
- Sonic reported revenue growth of 7% and net profit growth of 22% in the first half
Australia's health care services are funded by the Australian Government and by private health insurance. The country's public health care system is called Medicare, which provides health care for free or at reduced cost for Australian residents.
Talking about health care companies listed on the ASX, CSL is the largest in the sector in terms of market capitalisation, with nearly AU$131.32 billion.
Data source: ASX data as of 31 May 2022
Also read: Can Australia’s new Labor govt heal the cracks within health care system?
CSL is a global biotechnology leader specialising in vaccines for influenza, rare and serious diseases. The company is one of the largest and rapidly growing protein-based biotechnology businesses as well as a top provider of in-licenced vaccines.
CSL Behring and Seqirus are the two major segments of the company, which employs more than 25,000 people and caters to over 100 countries with its life-saving products.
Data source: company website
Recently, CSL tendered 74% of shares of Vifor Pharma, a global pharmaceutical company specialising in iron deficiency and cardio-renal therapies. The regulatory approval process for the acquisition is on track, and CSL is expecting to complete the transaction by mid-2022.
Ramsay Health Care Limited (ASX:RHC)
Ramsay provides quality health care through its private hospitals and day health care units. The company has global research, teaching, and clinical practice network spanning 10 countries and over 532 locations.
- Australia – 72 private hospitals and day surgery units
- Europe – Ramsay Santé operates in 350 locations across five countries
- UK - 34 acute hospitals and day procedure centres
- Asia - Ramsay Sime Darby Health Care Sdn Bhd operates in Indonesia, Malaysia, Hong Kong
For the quarter ended 31 March 2022, the company reported:
- Total revenue up 5.7%
- Net profit after tax down by 59%
The company attributed the decline in NPAT to the impact of COVID interruption on staff, patient and clinician availability and higher operation costs.
The shares of Ramsay have performed well and provided a 23% return to investors in the last 52-week period.
Sonic Healthcare Limited (ASX:SHL)
Sonic is one of the leading global health care providers. The company’s operations are as follows:
Laboratory medicine/ pathology
- Largest provider in Australia, Germany, and Switzerland with state-of-the-art laboratories
- Over 1,200 specialist pathologists and thousands of medical scientists and technicians
Radiology (Sonic Imaging Australia)
- Second-largest radiology provider in Australia
- More than 100 radiology centres
- Over 200 specialist radiologists and nuclear physicians, trained and experienced staff focused on providing the best service
Primary care medical services
- General practice clinics, remote health services, occupational health services, health assessment technologies, chronic disease management programs, etc.
Sonic reported revenue growth of 7%, Earnings Before Interest, Taxes, Depreciation & Amortisation (EBITDA) growth of 18% and net profit growth of 22% in the half-year ended 31 December 2021.
